|
1
|
Swerdlow HS, Campo E, Harris NL, Jaffe ES,
Pileri SA, Stein H, Thiele J and Vardiman JW: WHO Classification of
Tumors of Haematopoietics and Lymphoid Tissues. 2:(4th). IARC.
Lyon: 23–25. 2008.
|
|
2
|
Baxter EJ, Scott LM, Campbell PJ, East C,
Fourouclas N, Swanton S, Vassiliou GS, Bench AJ, Boyd EM, Curtin N,
et al: Cancer Genome Project: Acquired mutation of the tyrosine
kinase JAK2 in human myeloproliferative disorders. Lancet.
365:1054–1061. 2005. View Article : Google Scholar : PubMed/NCBI
|
|
3
|
Monte-Mór BDCR, da Cunha AF, Pagnano KBB,
Saad ST, Lorand-Metze I and Costa FF: JAK V617F prevalence in
Brazilian patients with polycythemia vera, idiopathic myelofibrosis
and essential thrombocythemia. Genet Mol Biol. 30:336–338. 2007.
View Article : Google Scholar
|
|
4
|
Jones AV, Kreil S, Zoi K, Waghorn K,
Curtis C, Zhang L, Score J, Seear R, Chase AJ, Grand FH, et al:
Widespread occurrence of the JAK2 V617F mutation in chronic
myeloproliferative disorders. Blood. 106:2162–2168. 2005.
View Article : Google Scholar : PubMed/NCBI
|
|
5
|
Levine RL, Wadleigh M, Cools J, Ebert BL,
Wernig G, Huntly BJ, Boggon TJ, Wlodarska I, Clark JJ, Moore S, et
al: Activating mutation in the tyrosine kinase JAK2 in polycythemia
vera, essential thrombocythemia, and myeloid metaplasia with
myelofibrosis. Cancer Cell. 7:387–397. 2005. View Article : Google Scholar : PubMed/NCBI
|
|
6
|
Véronèse L, Tchirkov A, Richard-Pebrel C,
Ledoux-Pilon A, Fleury J, Chaleteix C, Goumy C, Gouas L, Berger MG,
Vago P, et al: A thrombocytosis occurring in Philadelphia positive
CML in molecular response to imatinib can reveal an underlying
JAK2(V617F) myeloproliferative neoplasm. Leuk Res. 34:e94–e96.
2010. View Article : Google Scholar : PubMed/NCBI
|
|
7
|
Conchon MR, Costa JL, Novaes MM,
Dorlhiac-Llacer PE, de Alencar Fischer, Chamone D and Bendit I:
Simultaneous detection of JAK2 V617F mutation and Bcr-Abl
translocation in a patient with chronic myelogenous leukemia. Int J
Hematol. 88:243–245. 2008. View Article : Google Scholar : PubMed/NCBI
|
|
8
|
Bee PC, Gan GG, Nadarajan VS, Latiff NA
and Menaka N: A man with concomitant polycythaemia vera and chronic
myeloid leukemia: The dynamics of the two disorders. Int J Hematol.
91:136–139. 2010. View Article : Google Scholar : PubMed/NCBI
|
|
9
|
Pieri L, Spolverini A, Scappini B, Occhini
U, Birtolo S, Bosi A, Albano F, Fava C and Vannucchi AM:
Concomitant occurrence of BCR-ABL and JAK2V617F mutation. Blood.
118:344–346. 2011. View Article : Google Scholar
|
|
10
|
Cross NC, Melo JV, Feng L and Goldman JM:
(1994) An optimized multiplex polymerase chain reaction (PCR) for
detection of BCR-ABL fusion mRNAs in haematological disorders.
Leukemia. 8:186–189. 1994.PubMed/NCBI
|
|
11
|
Cross NC, White HE, Müller MC, Saglio G
and Hochhaus A: Standardized definitions of molecular response in
chronic myeloid leukemia. Leukemia. 26:2172–2175. 2012. View Article : Google Scholar : PubMed/NCBI
|
|
12
|
Ribeiro BF, Vergílio BR, Miranda EC,
Almeida MH, Delamain MT, da Silveira RA, de Souza CA, Albuquerque
DM, Dos Santos A, Duarte VO, et al: BCR-ABL1 transcript levels at 3
and 6 months are better for identifying chronic myeloid leukemia
patients with poor outcome in response to second-line
second-generation tyrosine kinase inhibitors after imatinib
failure: A report from a single institution. Acta Haematol.
134:248–254. 2015. View Article : Google Scholar : PubMed/NCBI
|
|
13
|
Jallades L, Hayette S, Tigaud I, Johnston
A, Coiffier B, Magaud JP and Ffrench M: Emergence of
therapy-unrelated CML on a background of BCR-ABL-negative JAK2
V617F-positive chronic idiopathic myelofibrosis. Leuk Res.
32:1608–1610. 2008. View Article : Google Scholar : PubMed/NCBI
|
|
14
|
Pingali SR, Mathiason MA, Lovrich SD and
Go RS: Emergence of chronic myelogenous leukemia from a background
of myeloproliferative disorder: JAK2 V617F as a potential risk
factor for BCR-ABL translocation. Clin Lymphoma Myeloma. 9:E25–E29.
2009. View Article : Google Scholar : PubMed/NCBI
|
|
15
|
Toogeh G, Ferdowsi S, Naadali F,
Alimoghaddam K, Ghavamzadeh A, Shirkoohi R and Ghaffari SH:
Concomitant presence of JAK2 V617F mutation and BCR-ABL
translocation in a pregnant woman with polycythemia vera. Med
Oncol. 28:1555–1558. 2011. View Article : Google Scholar : PubMed/NCBI
|
|
16
|
Ursuleac I, Colita A, Adam T, Jardan C,
Ilea A and Coriu D: The concomitant occurrence of JAK2 V617F
mutation and BCR/ABL transcript with phenotypic expression - an
overlapping myeloproliferative disorder or two distinct diseases? -
case report. J Med Life. 6:34–37. 2013.PubMed/NCBI
|
|
17
|
Pagnano KBB, Almeida D, Delamain MT, De
Souza AC and Lorand-Metze I: JAK2 V617F mutation evaluation of
chronic myeloid leukemia and acute myeloid leukemia. Rev Bras
Hematol Hemoter. 31:1692009.(In Portuguese).
|
|
18
|
Wahlin A and Golovleva I: Emergence of
Philadelphia positive chronic myeloid leukaemia during treatment
with hydroxyurea for Philadelphia negative essential
thrombocythaemia. Eur J Haematol. 70:240–241. 2003. View Article : Google Scholar : PubMed/NCBI
|
|
19
|
Mizutani S, Kuroda J, Shimizu D, Horiike S
and Taniwaki M: Emergence of chronic myelogenous leukemia during
treatment for essential thrombocythemia. Int J Hematol. 91:516–521.
2010.
|
